All In Biotech

Drug Trial Radar · NCT02629159

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate

A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Are on a Stable Background of Methotrexate (MTX) and Who Have an Inadequate Response to MTX (MTX-IR)

Last checked: Nov 19, 2026Latest source record: Aug 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,629 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,629

Actual

Start

Dec 1, 2015

Primary completion

Oct 27, 2017

Study completion Sep 30, 2027

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Dec 14, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to assess efficacy, including inhibition of radiographic progression, and safety with upadacitinib versus placebo and versus an active comparator, adalimumab, in adults with with moderately to severely active rheumatoid arthritis (RA) who are on a stable background of methotrexate (MTX and who have an inadequate response to MTX.

Conditions

  • Rheumatoid Arthritis

Interventions

  • Placebo for AdalimumabDrug

    Administered by subcutaneous injection once every other week

  • AdalimumabDrug

    Administered by subcutaneous injection once every other week

  • Placebo for UpadacitinibDrug

    Tablets taken orally once a day

  • UpadacitinibDrug

    Tablets taken orally once a day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12Time frame: Baseline and Week 12
  2. Percentage of Participants Achieving Clinical Remission (CR) Based on DAS28(CRP) at Week 12Time frame: Week 12

Locations

370 sites in 44 countries. Site status is shown where the registry gives one.

  • Achieve Clinical Research, LLC /ID# 143136

    Birmingham, Alabama

  • AZ Arthritis and Rheum Assoc /ID# 143130

    Mesa, Arizona

  • SunValley Arthritis Center, Lt /ID# 143123

    Peoria, Arizona

  • Elite Clinical Studies, LLC /ID# 144881

    Phoenix, Arizona

  • AZ Arthritis and Rheum Researc /ID# 143080

    Phoenix, Arizona

  • AZ Arthritis and Rheum Researc /ID# 143121

    Phoenix, Arizona

  • AZ Arthritis & Rheuma Research /ID# 143131

    Phoenix, Arizona

  • Arizona Research Center, Inc. /ID# 144877

    Phoenix, Arizona

  • AZ Arthritis & Rheum Research /ID# 156093

    Sun City, Arizona

  • University of Arizona Cancer Center - North Campus /ID# 143114

    Tucson, Arizona

  • Osteoporosis Medical Center /ID# 153935

    Beverly Hills, California

  • T. Joseph Raoof, MD, Inc. /ID# 144884

    Encino, California

  • Rheumatology Ctr of San Diego /ID# 153747

    Escondido, California

  • C.V. Mehta MD, Med Corporation /ID# 143116

    Hemet, California

  • Allergy and Rheum Med Clin /ID# 146083

    La Jolla, California

  • Kotha and Kotha /ID# 161046

    La Mesa, California

  • TriWest Research Associates- La Mesa /ID# 143115

    La Mesa, California

  • Valerius Med Grp & Res Ctr /ID# 143120

    Los Alamitos, California

  • Discovery MM Services, Inc /ID# 163504

    Los Angeles, California

  • Desert Medical Advances /ID# 143097

    Palm Desert, California

  • Sierra Rheumatology /ID# 155672

    Roseville, California

  • Robin K. Dore MD, Inc /ID# 143090

    Tustin, California

  • Medvin Clinical Research /ID# 148362

    Whittier, California

  • Arthritis Assoc & Osteo Ctr /ID# 143122

    Colorado Springs, Colorado

  • Arthritis and Rheum Clin N. CO /ID# 156094

    Fort Collins, Colorado

  • AARDS Research, Inc. /ID# 154190

    Aventura, Florida

  • ZASA Clinical Research /ID# 143134

    Boynton Beach, Florida

  • Clinical Res of West FL, Inc. /ID# 143112

    Clearwater, Florida

  • International Medical Research /ID# 143132

    Daytona Beach, Florida

  • Lakes Research, LLC /ID# 145630

    Miami, Florida

  • FL Med Ctr and Research, Inc. /ID# 143081

    Miami, Florida

  • Ctr Arthritis & Rheumatic Dise /ID# 143135

    Miami, Florida

  • Precision Research Org, LLC /ID# 143092

    Miami Lakes, Florida

  • Advanced Clin Res of Orlando /ID# 154617

    Ocoee, Florida

  • Rheum Assoc of Central FL /ID# 145632

    Orlando, Florida

  • Omega Research Consultants /ID# 145635

    Orlando, Florida

  • HMD Research LLC /ID# 163292

    Orlando, Florida

  • Arthritis Research of Florida /ID# 143125

    Palm Harbor, Florida

  • Arthritis Center, Inc. /ID# 145647

    Palm Harbor, Florida

  • St. Anthony Comprehsve Res Ins /ID# 143095

    St. Petersburg, Florida

Showing 40 of 370 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.